Posters/Publications

oral

FASN inhibitor

MASH TAG

poster

Denifanstat showed anti-fibrotic effect both on conventional and digital pathology in a metabolic dysfunction-associated steatohepatitis (MASH) Phase 2b trial (FASCINATE-2)

MASH TAG

oral

AI-Based Digital Pathology Shows that Denifanstat Improves Multiple Parameters of Fibrosis and Reduces Progression to Cirrhosis in MASH patients with F2/F3

AASLD The Liver Meeting

poster

Denifanstat significantly improves liver fibrosis in difficult-to-treat MASH patients – Results from conventional and AI-based pathology from the phase 2b FASCINATE-2, a 52-week randomized, double-blind, placebo-controlled trial

AASLD The Liver Meeting

poster

Fatty acid synthase (FASN) inhibitor reduces atherosclerosis development in diet-induced dyslipidaemia LDL receptor knockout mice with MASH

AASLD The Liver Meeting

paper

Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial

The Lancet Gastroenterology & Hepatology

oral

Demonstrating denifanstat’s differentiated approach in MASH with mechanistic and clinical data showing direct anti-fibrotic activity

8th Annual MASH Drug Development Summit

poster

Combination of fatty acid synthase (FASN) inhibitor and thyroid hormone receptor beta (THRb) agonist resmetirom shows synergistic improvement of NAFLD activity score (NAS) within 6-weeks in diet-induced obese mice with biopsy-confirmed MASH

EASL International Liver Congress

poster

Combination of fatty acid synthase (FASN) inhibitor and thyroid hormone receptor beta (THRb) agonist, resmetirom, improved markers of MASH and cardiovascular health in LDL receptor knockout MASH mice

EASL International Liver Congress

oral

Denifanstat, a fatty acid synthase (FASN) inhibitor, shows significant fibrosis improvement and MASH resolution in FASCINATE-2, a Ph2b 52 week global, randomized, double blind, placebo-controlled trial in patients with F2 or F3 fibrosis

EASL International Liver Congress

Scroll to Top